The use of Complementary and alternative medicines two years
The use of Complementary and alternative medicines two years after cancer
diagnosis in France – evidence from the VICAN survey.
Aline Sarradon-Eck1,2, Anne-Déborah Bouhnik1,2, Dominique Rey1,2,3, Marc-Karim Bendiane1,2,3 Patrick
Peretti-Watel1,2 and the VICAN group
1. INSERM, UMR912 «Economics and Social Sciences Applied to Health & Analysis of Medical Information» (SESSTIM), 13006,
2. Aix Marseille University, UMR_S912, IRD, 13006, Marseille, France.
3. ORS PACA, Southeastern Health Regional Observatory, 13006, Marseille, France
To evaluate the use of CAM in a representative sample of patients 2 years after a cancer diagnosis.
To determine the profile of CAM-users in terms of :
n nIncrease in the use of Complementary and alternative medicine (CAM), especially in the
context of chronic diseases
n nA growing number of studies focus on the use of CAM in cancer
è èSocio-economic characteristics
è èMedical characteristics
n nEstimated rates of use varies according to countries and localisations (Molassiotis, 2005) : from
15% to 73% in Europe
n nFew data in France : 34% (Trager-Maury, 2007)
n nHowever, existing results need to be interpreted with caution, mainly due to recruitment bias
USE OF THE VICAN SURVEY (BOUHNIK ET AL, BMJ OPEN 2015)
FACTORS ASSOCIATED WITH CAM USE n n16.4% of participants used CAM at time of the survey :
45,1% of them used CAM since diagnosis
66.0% reported only one type of CAM
22.2% reported 2 types of CAM
11.8% reported more than 2 types of CAM
70 and more
Social Deprivation Index
Level of education
<High school certificate
≥High school certificate
Types of CAM used (1/2)
Alternative medical system
Representative sample of patients, two years after cancer diagnosis.
Objective : to describe life conditions of cancer survivors
12 localisations : breast cancer, prostate cancer, colorectal cancer, cervical cancer, endometrial
cancer, melanoma, bladder cancer, kidney cancer, lung cancer, upper aerodigestive tract, non-Hodgkin
lymphoma, thyroid cancer
Selection of patients among individuals registered in one of the three main Health Insurance Schemes
which together cover more than 90% of the French population.
Data collected in 2012 / 4349 patients included (response rate=43.7%)
Questions about CAM use : CAM use at time of the survey (yes/no)
If yes, use of CAM before diagnosis (yes/no) and type of CAM used (open-question)
Manipulation and body-based methods
Types of CAM used (2/2)
Biologically based therapies
COMBINATION OF THREE SOURCES OF DATA
medical survey with the physician
who iniated treatment
Paents-reported outcomes collected
using the CATI system
Estimation of CAM-use in a representative sample of patients, 2 years after diagnosis
lower than what found in other surveys.
Fatigue clinically significant
Associated factors mainly related to socio-economic characteristics.
members of the VICAN group : Thomas APARICIO, Emmanuel BABIN, François BECK, Robert BENAMOUZIG, Marc-Karim BEN
DIANE, Cyril BERENGER, Dominique BESSETTE, Anne-Déborah BOUHNIK, Philippe-Jean BOUSQUET, Marie-Claude CABANELGICQUEL, Marianick CAVALLINI-LAMBERT, Michèle CHANTRY, Claire CHAUVET, Sébastien CORTAREDONA, Véronique DANGUY,
Michel DORVAL, Jean-Baptiste HERBET, Laetitia HUIART, Xavier JOUTARD, Anne-Gaëlle LE CORROLLER-SORIANO, Julien
MANCINI, Mégane MERESSE, Jean-François MORERE, Herman NABI, Alain PARAPONARIS, Patrick PERETTI-WATEL, Marie
PREAU, Christel PROTIERE, Frédérique RETORNAZE, Dominique REY, Benoit RIANDEY, Luis SAGAON-TEYSSIER, Aurélia TISON,
Valérie SEROR, Archana SINGH-MANOUX, Catherine THIEBLEMONT, Pierre VERGER.
For nearly half of CAM-users, cancer was an initiating factor for using such medicines.
This study was funded by The National Institute of Cancer (INCa),“Contrat de recherche et développement no 05-2011”.
Types of CAM-use and associated factors similar to those encountered in the literature.
Medico-administrave records including
financial reimbursement data and hospital
discharge records (SNIRR-AM database)
Contact : [email protected]